RJA
ALDX icon

Raymond James & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Raymond James & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$188K Buy
34,884
+251
+0.7% +$1.2K ﹤0.01% 3664
2024
Q2 		$115K Sell
34,633
-1,391
-4% -$5.45K ﹤0.01% 3713
2024
Q1 		$118K Buy
36,024
+3,240
+10% +$10.7K ﹤0.01% 3713
2023
Q4 		$115K Sell
32,784
-18,267
-36% -$56.4K ﹤0.01% 3629
2023
Q3 		$341K Sell
51,051
-761
-1% -$5.65K ﹤0.01% 3120
2023
Q2 		$435K Buy
51,812
+24,970
+93% +$246K ﹤0.01% 3024
2023
Q1 		$267K Buy
26,842
+1,173
+5% +$8.29K ﹤0.01% 3312
2022
Q4 		$179K Sell
25,669
-1,380
-5% -$7.89K ﹤0.01% 3494
2022
Q3 		$144K Sell
27,049
-4,177
-13% -$25.1K ﹤0.01% 3532
2022
Q2 		$125K Buy
31,226
+4,920
+19% +$16.9K ﹤0.01% 3634
2022
Q1 		$117K Buy
26,306
+4,609
+21% +$18.4K ﹤0.01% 3791
2021
Q4 		$87K Sell
21,697
-24,150
-53% -$184K ﹤0.01% 3882
2021
Q3 		$403K Sell
45,847
-495
-1% -$4.54K ﹤0.01% 3217
2021
Q2 		$525K Buy
46,342
+24,042
+108% +$289K ﹤0.01% 3042
2021
Q1 		$265K Sell
22,300
-498
-2% -$5.74K ﹤0.01% 3440
2020
Q4 		$156K Hold
22,798
– – ﹤0.01% 3472
2020
Q3 		$169K Buy
22,798
+698
+3% +$4.51K ﹤0.01% 3272
2020
Q2 		$92K Sell
22,100
-2,500
-10% -$9.13K ﹤0.01% 3300
2020
Q1 		$61K Buy
24,600
+2,000
+9% +$8.99K ﹤0.01% 3291
2019
Q4 		$131K Buy
22,600
+400
+2% +$2.31K ﹤0.01% 3438
2019
Q3 		$117K Buy
22,200
+5,100
+30% +$27.5K ﹤0.01% 3367
2019
Q2 		$103K Buy
+17,100
New +$129K ﹤0.01% 3404

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James & Associates's ALDX Position: Q3 2024 in Review

Raymond James & Associates increased its Aldeyra Therapeutics (ALDX) stake by 0.72% in Q3 2024, buying an estimated $1.2K and bringing the position to 34,884 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Raymond James & Associates first reported a position in ALDX in Q2 2019 and has held it in 22 quarters since. The position peaked at $525K in Q2 2021. 112 funds tracked by Wall St. Rank hold ALDX as of Q3 2024.

  • Raymond James & Associates held 34,884 shares of Aldeyra Therapeutics worth $188K as of Q3 2024.
  • Raymond James & Associates bought 251 Aldeyra Therapeutics shares in Q3 2024, an estimated $1.2K.
  • Aldeyra Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3664 holding.
  • Raymond James & Associates first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • Raymond James & Associates's Aldeyra Therapeutics position peaked at $525K in Q2 2021.
  • 112 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.